Clinical trial NCT05848284: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation ( VISTA-US)
Official title: Clinical Safety and Efficacy of the VDyne Transcatheter Tricuspid Valve Replacement System for the Treatment of Tricuspid Regurgitation
Study type: INTERVENTIONAL
Overall status: RECRUITING
Phase: NA
Conditions: Tricuspid Regurgitation
Tricuspid Valve Disease
Tricuspid Valvular Disorders
Keywords: VDyne
Lead sponsor: VDyne, Inc.
Sponsor class: INDUSTRY
First posted: 2023-05-08
Enrollment: 30
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this clinical study is to evaluate the safety and clinical efficacy of the VDyne System in the treatment of symptomatic severe tricuspid regurgitation (TR).


Eligibility criteria: Inclusion Criteria:

* Symptomatic severe tricuspid valve regurgitation of primary or secondary etiology.
* NYHA class ≥ II. If NYHA Class IV, patient must be ambulatory.
* Subject is adequately treated with medical therapy for heart failure ≥ 30 days prior to
* index procedure, including a diuretic.
* Heart Team determines patient is a recommended candidate for the VDyne System.
* Age \>18 years at time of index procedure.
* Clinical Screening Committee (CSC) and Imaging Core Labs confirm suitability for treatment with the VDyne System.

Exclusion Criteria:

* Patient anatomy (cardiac and vascular) is not suitable for VDyne System as assessed by Imaging Core Labs, Sponsor or Clinical Screening Committee (CSC)
* Intolerance to procedural anticoagulation or post-procedural antiplatelet/ anticoagulation regimen that cannot be medically managed
* Hypersensitivity to nickel or titanium
* Left Ventricular Ejection Fraction (LVEF) \<30%.
* Severe RV dysfunction.
* Significant abnormalities of the tricuspid valve and sub-valvular apparatus.
* Sepsis including active infective endocarditis (IE) (within last 6 months).
* Right ventricular, atrial thrombus, vegetation or mass on tricuspid valve.
* Severe tricuspid annular or leaflets calcification.
* Systolic pulmonary hypertension with systolic pulmonary artery pressure \>70 mmHg.
* History or rheumatic fever
* Significant coronary artery disease requiring treatment such as symptomatic, unresolved multi-vessel or unprotected left main coronary artery disease.
* Any planned surgery or interventional procedure within 30 days prior to or 30 days following the implant procedure. This includes any planned concomitant cardiovascular procedure such as CABG, PCI, pulmonary vein ablation, left atrial appendage occlusion, septal defect repair, etc.
* Unresolved severe symptomatic carotid stenosis (\> 70% by ultrasound).
* Cardiac resynchronization therapy device or implantable pulse generator implanted within 60 days of planned implant procedure.
* Permanent pacing leads that will interfere with delivery or implantation of the VDyne Valve.
* Cardiogenic shock or hemodynamic instability requiring inotropes or mechanical support devices at the time of planned implant procedure.
* Prior tricuspid valve surgery or catheter-based therapy with permanent residual device(s) implanted that would preclude delivery or implantation of the VDyne Valve (e.g. valve replacement, edge to edge repair, etc.).
* Significant valvular heart disease requiring intervention other than the tricuspid valve.
* Known significant intracardiac shunt (e.g. septal defect)
* Cerebrovascular accident (stroke, TIA) within 6 months of treatment procedure.
* Severe lung disease (severe COPD or continuous use of home oxygen or oral steroids).
* Acute myocardial infarction (AMI) within 30 days.
* Significant renal dysfunction (eGFR\<30 ml/min/1.73m2) or on dialysis.
* End-stage liver disease (MELD \> 11 / CHILD class C).
* Bleeding requiring transfusion within prior 30 days.
* Coagulopathy or other clotting disorder that cannot be medically managed.
* Chronic immunosuppression or other condition that could impair healing response.
* Any of the following: leukopenia, chronic anemia (Hgb \< 9), thrombocytopenia, history of bleeding diathesis, or coagulopathy.
* Unwilling to receive blood products.
* Known hypersensitivity or contraindication to procedural or post-procedural medications (e.g., contrast solution) which cannot be adequately managed medically.
* Life expectancy less than 12 months due to non-cardiac comorbidities.
* Treatment is not expected to provide benefit (futile).
* Current IV Drug user (must be free drug abuse for \> 1 year).
* Pregnant, lactating or planning pregnancy within next 12 months.
* Vulnerable patient groups (minors, cognitively impaired persons, prisoners, persons whose willingness to volunteer could be unduly influenced by the expectation of benefits associated with participation or of retaliatory response from senior members of a hierarchy in case of refusal to participate, such as students, residents, and employees).
* Currently participating in an investigational drug or device trial that has not reached its primary endpoint or is likely to interfere with this study.
* Patient (or legal guardian) unable or unwilling to provide written, informed consent before study enrollment.
* Patient unable or unwilling to comply with study required testing and follow-up visits

Primary outcomes:
measure: The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) within 30 days of the procedure, as classified by the Clinical Events Committee (CEC).
timeFrame: Implant to 30 days post-procedure
measure: Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
timeFrame: Baseline to 1 month after implant
measure: Changes in symptom status (NYHA class)
timeFrame: Baseline to 1 month after implant
measure: Changes in functional capacity (6-minute walk test)
timeFrame: Baseline to 1 month after implant
measure: Changes in in quality of life (KCCQ score)
timeFrame: Baseline to 1 month after implant
Secondary outcomes:
measure: The percentage of subjects with Device- and/or Procedure-related Major Adverse Events (MAE) after 30 days to 1 year of the procedure, as classified by the Clinical Events Committee (CEC).
timeFrame: 30 days post-procedure to 1 year
measure: Change in tricuspid valve regurgitation compared to baseline as measured by the Imaging Core Labs
timeFrame: 1 month after implant to 1 year post-implant
measure: Changes in right ventricle as measured by core lab
timeFrame: 1 month after implant to 1 year post-implant
measure: Rate of heart failure hospitalization
timeFrame: 1 month after implant to 1 year post-implant
measure: Changes in symptom status (NYHA class)
timeFrame: 1 month after implant to 1 year post-implant
measure: Changes in functional capacity (6-minute walk test)
timeFrame: 1 month after implant to 1 year post-implant
measure: Changes in in quality of life (KCCQ score).
timeFrame: 1 month after implant to 1 year post-implant
Other outcomes:
Locations:
city: Thousand Oaks
country: United States
facility: Los Robles Hospital and Medical Center
state: California
city: Detriot
country: United States
facility: Henry Ford Hospital
state: Michigan
city: Minneapolis
country: United States
facility: Minneapolis Heart Institute Foundation
state: Minnesota
city: Rochester
country: United States
facility: Mayo Clinic - Rochester
state: Minnesota
city: Bronx
country: United States
facility: Montefiore Medical Center
state: New York
city: New York
country: United States
facility: Columbia University Medical Center/NYPH
state: New York
city: Portland
country: United States
facility: Oregon Health and Science Unversity
state: Oregon
city: Charleston
country: United States
facility: Medical University of South Carolina
state: South Carolina
city: Nashville
country: United States
facility: Ascension St. Thomas
state: Tennessee
city: Québec
country: Canada
facility: Québec-Université Laval (IUCPQ-ULaval)
state: Quebec
Study officials:
References: